What changed in Roivant Sciences Ltd.'s latest annual report
In the year ended 31 Mar 2026, Roivant Sciences Ltd.'s revenue fell 71.6% to USD 8.26m, from USD 29.05m; total liabilities rose 66.7% to USD 416.27m, from USD 249.74m; cash and cash equivalents fell 47.7% to USD 1.42bn, from USD 2.72bn.
Year ended 31 Mar 2026. Source: 10-K filed 20 May 2026, read it on SEC EDGAR.
USD 29.05m to USD 8.26m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 29.05m | 8.26m | Down 71.6% |
| Net income | -171.98m | -299.77m | Not comparable |
| Total assets | 5.44bn | 5.71bn | Up 5% |
| Total liabilities | 249.74m | 416.27m | Up 66.7% |
| Cash and cash equivalents | 2.72bn | 1.42bn | Down 47.7% |
| Shareholders' equity | 4.69bn | 4.53bn | Down 3.4% |
Questions people ask
Did Roivant Sciences Ltd.'s revenue grow last year?
Revenue fell 71.6%, from USD 29.05m to USD 8.26m in the year ended 31 Mar 2026.
Is Roivant Sciences Ltd. profitable?
Not in its latest year: it reported a net loss of USD 299.77m in the year ended 31 Mar 2026. The year before: a net loss of USD 171.98m.
How much cash and debt does Roivant Sciences Ltd. have?
At its latest year end (31 Mar 2026), Roivant Sciences Ltd. reported cash and cash equivalents of USD 1.42bn.
Where do these numbers come from?
From Roivant Sciences Ltd.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Roivant Sciences Ltd.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%